Our companies

A portfolio of innovation
Accelerating mental healthcare solutions

ATAI Life Sciences is dedicated to bringing innovation to mental healthcare, a field that has seen little progress since the development of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) in the 1980s and 1990s, respectively.

Want to learn more about our companies?  Check them out below.

COMPASS Pathways

develops psilocybin therapy for patients with treatment-resistant depression.
compasspathways.com

Perception Neuroscience

develops arketamine therapy for patients with neuropsychiatric diseases.
perceptionneuroscience.com

DemeRx

developing ibogaine and noribogaine for the treatment of opioid use disorders
demerx.com

Innoplexus

leverages the power of AI and big data analytics for a variety of applications in life sciences, like drug development.
innoplexus.com

GABA Therapeutics

develops GRX-917 — a deuterated version of etifoxine — for anxiety.
gabarx.com

Neuronasal

preventing post-concussion injury and mental health complications by novel nose-to-brain drug delivery of NAC
neuronasal.com